Pathologic Tissue Injury and Inflammation in Mice Immunized with Plasmid DNA-Encapsulated DOTAP-Based Lipid Nanoparticles Authors: Shasha Peng, Yifan Zhang, Xin Zhao, Yibin Wang, Zihan Zhang, Xin Zhang, Jiali Li, Huiwen Zheng, Ying Zhang, Haijing Shi, Heng Li, Longding Liu Published: 2024 ABSTRACT Ionizable cationic lipids have been developed to mitigate the toxicity of quaternary ammonium lipids, such as DOTAP. Despite its toxicity, DOTAP can promote localization of lipid nanoparticles (LNPs) in target tissues, serving as one of the ionizable cationic helper lipids. Notably, DOTAP-based nanoadjuvants prepared via microfluidic methods showed a better T-cell response. Previous studies showed that DOTAP-based LNPs prepared by the lipid-film method resulted in obvious adverse events. Therefore, our research focused on evaluating the tissue localization and adverse toxicity of a DOTAP-based delivery system prepared through microfluidic techniques. We assessed the delivery efficacy, biodistribution, inflammatory response, and pathological injury in various tissues. In our study, the plasmid DNA encoding the receptor-binding domain (RBD) of SARS-CoV-2 was encapsulated using a mixture of lipids that included DOTAP, DOPE, cholesterol, and DMG-PEG2000 via microfluidic mixing. The LNP-RBDs were smaller than those prepared via the traditional lipid membrane system. We found that LNP-DNA complexes can be effectively delivered and expressed in muscle tissue, with specific antibodies in serum induced postimmunization. Initial distribution of the liposomes was observed in the muscle and liver. Interestingly, both LNPs and DNA showed sustained presence in the lungs and spleen in the group immunized with DNA-encapsulated DOTAP-based LNPs, whereas lower amounts of DNA were detected in the group immunized with dissociative DNA. We detected obvious inflammatory responses and pathological injuries in the muscle, heart, and liver, and the side effects decreased when the immunization dose decreased. These findings suggest that DOTAP-based LNPs have obvious advantages for targeting the lungs and spleen. Additionally, inflammatory responses and pathological injuries occur in a dose-dependent manner in the muscles, heart, and liver. In conclusion, these findings contribute to the development of an LNP delivery system with DOTAP, highlighting its potential to enhance tissue localization and promote high levels of expression when coordinated with ionizable lipids. Introduction Liposomes can serve as effective adjuvants and nanoparticle delivery systems for carrying therapeutic drugs, proteins, and nucleic acids, activating the innate immune response.1 Their biocompatibility, biodegradability, low toxicity, and immunogenicity are critical for new vaccine design.2 Lipid nanoparticles (LNPs) can effectively deliver COVID-19 mRNA vaccines; however, they may cause adverse events, such as injection site pain, redness, fatigue, headache, muscle pain, chills, nausea, and fever.3 LNPs can contain cationic lipids, PEGylated lipids, cholesterol, and helper lipids.4 Cationic lipid complexes with negatively charged nucleic acids enable drug delivery to cells,5 whereas PEGylated lipids increase LNP stability and prevent their phagocytosis.6 Additionally, cholesterol enables the fusion of LNPs with cell membranes,7 and helper lipids increase LNP encapsulation efficiency.8 DOTAP, a cationic lipid, facilitates the assembly of nucleic acids and proteins into nanoparticles, enhancing the immune response and promoting efficient cellular uptake.9−13 Moreover, the positive charge on the surface of DOTAP liposomes obviously affects the uptake of LNPs by macrophages and dendritic cells, thereby increasing antigen uptake and promoting immune cell presentation.14−17 LNP size must be controlled during preparation as it plays important roles in nanoparticle pharmacokinetics, biodistribution, delivery efficiency, and side immune reactions.18,19 Interestingly, small DOTAP-based nanoadjuvants (under 100 nm) prepared via a microfluidic system induced stronger T-cell responses than DOTAP-based LNPs prepared via a lipid film hydration method.16 However, there have been few reports on DOTAP-based LNPs prepared via microfluidic systems for use in vaccines or drug delivery. Nucleic acid immunization is a method used to develop advanced vaccines that effectively trigger both humoral and cell-mediated immune responses.20,21 DNA vaccines offer advantages over conventional live or attenuated vaccines by inducing broad immune responses without the risk of replicating microbes, stimulating cellular and humoral immunity, and enabling the encoding of multiple antigens in a single vaccine.21,22 Our research aimed to investigate the transfection efficacy, tissue distribution, abundance, and degree of inflammation-related pathological injury following immunization with DNA encapsulated by LNPs. In our study, LNPs generated via DOTAP and plasmid DNA (pDNA) encoding the receptor-binding domain (RBD) protein of SARS-CoV-2 were prepared via microfluidics, resulting in LNPs with an average size of 80 nm and a stable structure. The prepared LNP-DNA complexes promoted high protein expression in muscles and elicited robust antibody release. They are also widely distributed in muscle, liver, lung, and splenic tissues. Immunization with LNPs-DNA led to high levels of inflammation and reversible pathological injuries, which decreased with a decreasing immunization dose. Results Plasmid DNA-Encapsulated DOTAP-Based LNPs Were Generated via a Microfluidics System with High Encapsulating Efficiency LNPs were formulated using DOTAP/DOPE/cholesterol/DMG-PEG2000 at a mass ratio of 1:0.76:0.55:0.256. The lipids were mixed with pDNA at a mass ratio of 7.5-fold via microfluidics under a flow rate of 3 mL/min. Following dialysis in phosphate-buffered saline (PBS) (pH 7.4), the size, homogeneity, and morphology were assessed via dynamic light scattering, transmission electron microscopy (TEM), and scanning electron microscopy (SEM) (Figure 1A–D). The LNPs exhibited a spherical structure with a size of approximately 80 nm (Figure 1A–C). Interestingly, LNPs-DNA and empty LNPs (eLNPs, encapsulated with PBS) had different structures according to TEM, and LNPs-DNA had a multilayered internal structure, while no layers formed in the eLNPs (Figure 1A,F). Zeta potential detection in PBS revealed that LNPs-DNA were positively charged at approximately 17.0, while eLNPs were weakly positively charged at approximately 6.31, and free DNA was negatively charged at approximately −30.1 (Figure 1D). Similarly, in the TAE electrophoretic buffer system, LNPs-RBD were weakly positively charged (in the negative pole direction) and DNA migrated in the positive direction after Triton X-100 lysis, indicating that these molecules were negatively charged. Moreover, the mobility of LNPs-DNA after lysis was slower than that of naked DNA, which may be affected by the molecular size or the number of charges (Figure 1E). In addition, electrophoresis via TAE demonstrated good DNA integrity in the LNPs (Figure 1E). LNPs-RBD could be stored for approximately 15 days without a protectant and for over 84 days with a protectant containing 10% sucrose (Figure 1F). Importantly, we demonstrated that the encapsulation efficiency was greater than 95% (Figure 1G), and no significant decrease in the encapsulated DNA content (Figure 1G) and quantities (Figure 1H) was detected after storage for 15 days without a protectant or for over 84 days with a protectant containing 10% sucrose. DOTAP-based LNPs can encapsulate DNA to generate a stable structure of approximately 80 nm with high encapsulation efficiency and stability. (A) Detection of LNPs-RBD and eLNPs via TEM. (B) Detection of LNPs-DNA and eLNPs via SEM. (C) Size distribution of LNP-DNAs and eLNPs detected by dynamic light scattering. (D) Zeta potential of DOTAP lipids, DNA, eLNPs, and LNPs-RBD by dynamic light scattering. (E) LNP-DNAs were detected in a TAE electrophoretic buffer system. The first lane contained plasmid DNA, the second lane contained intact LNPs-DNA, and the third lane contained LNPs-DNA after lysis with 5% Triton X-100. (F) LNPs-RBD were detected via TEM after they were stored at 4 °C without a protectant for 15 days and at −80 °C with a protectant containing 10% sucrose for 84 days. (G) The encapsulation efficiency was calculated from the quantities of DNA detected using the Quant-iT PicoGreen dsDNA reagent. (H) The total quantities of DNA in LNPs were detected using the Quant-iT PicoGreen dsDNA reagent. The scales in (A, B, and F) are 100 nm. Weak Inflammation Responses and Pathological Injuries Were Observed after Immunization with DOTAP, with Injury Levels Similar to Those after Immunization with SM-102 and C12-200 The cytotoxicity, inflammatory responses, and pathological injuries in mice by intramuscular injection were detected and compared between DOTAP and other cationic lipids including DSDMA, DOTMA, and DODAP, or ionizable lipids including DlinDMA, C12-200, SM-102, and ALC-0315. Regarding cytotoxicity, LDH release assays revealed that the rates of cell mortality were greater in the DlinDMA, DODAP, SM-102, and ALC-0315 groups, and the cytotoxicity of DOTAP in the cells was milder (Figure 2A). Equal quantities of various lipids (30 μg) were separately then administered to the mice via intramuscular injection, and the resulting inflammatory responses and pathological injuries were compared. Most lipids elicited similar inflammatory responses in the muscle and liver, especially in the pro-inflammatory responses, and the increased levels of inflammatory cytokines in the liver were more obvious. There were weaker inflammatory cytokine responses in the groups immunized with DlinDMA and DSDMA. Pathological injury detection revealed obvious injuries in the muscle but mild injuries in the heart and liver after immunization with these lipids. In the muscle, there was no significant difference in pathological injuries present between the groups immunized with DOTAP and ionizable lipids, including SM-102 and C12–200. Overall, weak inflammatory response and pathological injuries were observed after immunization with DOTAP, and the injury levels were similar to those after immunization with ionizable lipids including SM-102 and C12-200. Weak inflammatory responses and pathological injuries present after immunization with DOTAP. (A) Cationic or ionizable lipids were separately transfected, and the absorbance value of LDH detection was detected to determine the cell death ratio. (B) The RNA abundance of inflammation-associated cytokines in the tissues of mice immunized with cationic or ionizable lipids was measured via RT-PCR. The primers used for RT-PCR are described in detail in Table S1. (C) Pathological injuries were detected by H&E staining in the muscle, heart, and liver from the mice immunized with cationic or ionizable lipids. The tissues were collected at 4 h and 4 days after immunization. Pathology score rules are described in Table S2. The red arrow points to vascular congestion and tissue hemorrhage; the blue arrow indicates inflammatory cell infiltration, disordered arrangement, and partial rupture of myofibrils; and the black arrow indicates cellular necrosis and tissue disintegration. DOTAP-Based LNPs Could Efficiently Transfect pDNA-RBD, Leading to Durable and High Levels of RBD Protein Expression in Muscles and Inducing a Specific Antibody Response in Serum in Mice The delivery efficiency and gene expression of the pDNA-encapsulated DOTAP-based LNP were detected in 293T cells and mice. Transfection experiments revealed that LNPs-RBD and eLNPs could be efficiently transfected into 293T cells within 24 h (Figure 3A,B). High levels of RBD protein were expressed in most cells at 48 h after transfection, and the expression efficiency was similar between the groups treated with LNPs and the commercial transfection reagent FuGENE HD (Promega; Figure 3C,D). Western blot analysis and immunohistochemistry (IHC) experiments revealed that RBD protein was present at high level in the muscles in the LNP-RBD (5 and 10 μg) and DNA-RBD (10 μg) groups immunized via intramuscular injection (Figure 3E,F). Antigen expression began to appear at 4 h, and the levels increased significantly beginning at 24 h. Notably, the antigen expression level in the pDNA-immunized group began to decrease and was lower than that in the other groups at 4 days (Figure 3E); additionally, the antigen expression levels in the high- and low-dose LNP-DNA groups began to decrease at 14 days in muscle with no obvious antigen present at 28 days (Figure 3E). Interestingly, we found that RBD protein was mostly expressed in immune cells or inoblast cells in the areolar area of muscle tissues (Figure 3F). Anti-RBD antibody in the serum appeared after 7 days of immunization, and higher levels were presented in the LNP-RBD (10 μg) group than in the dissociative DNA (10 μg) group from 14 days, while higher levels were presented in the LNP-RBD (5 μg) group than in the dissociative DNA (10 μg) group, and there was no significant difference between the 5 and 10 μg-immunized LNP-RBD groups at 28 days (Figure 3G). DOTAP-based LNPs could efficiently transfect pDNA-RBD, leading to durable and high levels of RBD protein expression in muscles and inducing specific antibody responses in mice. (A, B) Immunofluorescence detection of an anti-PEG2000 antibody in 293T cells transfected with LNPs-RBD (A) or eLNPs (B) and the anti-PEG antibody is shown in red. (C) RBD protein detection by immunofluorescence in the groups transfected with LNPs or FuGENE HD was performed at 48 h. (D) Western blot detection of RBD protein in 293T cells. (E) Western blot detection of anti-RBD antibodies in the muscle in the DNA (10 μg) and LNP-RBD (5 and 10 μg) groups. (F) IHC detection of anti-Spike RBD antibodies in the muscle in the same 3 groups. The red arrows represent immune cells, and the black arrows represent inoblast cells. (G) Serum samples were collected from the PBS, DNA, and LNPs-RBD (5 and 10 μg) groups to quantify antibody levels via ELISA. LNPs and DNA Presented Durably with Obvious Abundance in the Lungs and Spleen in the Mice Immunized with DNA-Encapsulated DOTAP-Based LNPs The distributions of LNPs after immunization with LNPs-DNA were detected by immunofluorescence with the anti-PEG2000 antibody, and the distributions of DNA after immunization with LNPs-DNA or dissociative DNA were detected by FISH with Cy3-labeled probes (Figure 4). We observed PEG2000 and DNA signals in the muscle, heart, liver, spleen, lungs, and small intestine, and interestingly, spatial and temporal disparities were present among these tissues. In the muscles, both PEG2000 and DNA exhibited high abundance, and then, the abundance of PEG2000 decreased and disappeared at 4 days. DNA exhibited obvious abundance from 4 h to 4 days and then disappeared at 14 days in the mice immunized with LNPs-DNA, whereas the richness of DNA decreased after 24 h and disappeared at 7 days in the mice immunized with dissociative DNA. In the heart and liver, PEG2000 was present for a short time and presented from 4 to 24 h in the heart while presented just for 4 h in the liver; however, DNA was observed durably from 4 h to 7 days in both groups after immunization with LNPs-DNA and dissociative DNA, with more DNA observed in the heart in the group immunized with dissociative DNA. Interestingly and importantly, in the lungs and spleen, obvious abundance of both PEG2000 and DNA were observed and maintained from 4 h to 4 days and then disappeared at 28 days in the groups after immunization with LNPs-DNA. After immunization with dissociative DNA, DNA was present from 4 h to 4 days, and high abundance appeared only at 24 h. In addition, LNP distribution in the small intestine began at 24 h after immunization and persisted for 7 days, whereas LNP abundance was not obvious, and the distribution and abundance of DNA were consistent with those of LNPs, with only a small amount of DNA present at 24 and 48 h after immunization with dissociative DNA (Figure 4). Similarly, we evaluated the distribution and abundance of eLNPs without DNA after immunization with an equal molar mass, and we found that the distribution and abundance followed patterns similar to those of the LNPs-DNA (Figure S1). LNPs and DNA were present in various tissues in mice immunized with DNA-encapsulated DOTAP-based LNPs. The distribution and abundance of LNPs detected by an antibody against PEG2000 in the muscle, heart, liver, lungs, spleen, and small intestine of BALB/c mice after immunization with LNPs-RBD via intramuscular injection; the PEG2000 signals are shown in red. The distributions of DNA after immunization with LNPs-DNA or dissociative DNA were detected by FISH with Cy3-labeled probes, and Cy3 signals are shown in yellow. The probe sequence was as follows: 5′ CCATAAGTGGGTCGGAAACCATATGATCGTAAAGGAAAGTAACAATTAAAACCTGCAACACCATTACAAGGT. Transient Inflammatory Responses Were Observed in the Mice Immunized with LNPs The expression levels of inflammation-associated cytokines in the tissues of the mice were determined via RT-PCR. First, the levels of inflammation-associated cytokines in the peripheral blood of mice that received DOTAP-associated lipid injection were detected 48 h after immunization. The RANTES and MMP9 levels increased significantly in the eLNP group, whereas the CXCL1 and CXCL5 levels increased in the LNP-RBD (10 μg) and DOTAP groups (Figure 5A). Then, inflammation responses in various tissues revealed that the most severe inflammatory responses were present in the muscle, followed by the heart and liver, and inflammation was not obvious in other tissues. In the muscle, most proinflammatory cytokine levels increased drastically from 4 h to 4 d after immunization with LNPs-RBD, and anti-inflammatory cytokine levels subsequently increased at 4 d. Moreover, proinflammatory cytokine levels increased primarily at 4 h after immunization with DNA, and the levels of the proinflammatory cytokine levels increased from 4 h to 7 d after immunization with eLNPs or DOTAP. In the heart, the levels of most proinflammatory and anti-inflammatory cytokines were increased at 48 h after immunization with DNA, whereas the levels of inflammatory factors were slightly increased in the other immunization groups. In the liver, the levels of some proinflammatory cytokines and anti-inflammatory cytokines increased from 4 h to 7 d after immunization with eLNPs and DOTAP, whereas the levels of inflammatory factors slightly increased in the other immunization groups. Interestingly, the inflammatory cytokine levels were dose-dependent in most tissues (Figure 5B). High levels of inflammatory factors were transiently present in various tissues after immunization with LNPs or their components. (A) Changes in the RNA abundance of inflammation-associated cytokines in the peripheral blood in the DOTAP-associated lipid injection groups. (B) The RNA abundance of inflammation-associated cytokines in the tissues of mice immunized with LNP components was measured via RT-PCR. The changes in the muscle are colored red with values ranging from 0 to 6000, and the changes in the heart and liver are colored blue with values ranging from 0 to 1500. The primers used for RT-PCR are described in detail in Table S1. Obvious Pathological Injuries were Present in the Lungs, Heart, and Liver after Immunization with DNA-Encapsulated DOTAP-based LNPs, and Most Injuries Recovered after 28 Days. Hematoxylin and eosin (H&E) staining was performed to detect pathological changes in the muscle, heart, liver, lungs, small intestine, and spleen of mice immunized with LNPs-RBD, eLNPs, or their components including dissociative DNA, DOTAP, DOPE, and DMG-PEG2000 (Figures 6, S2–S4). All of the mice immunized with DOTAP-based LNP survived, and the mice lost <10% of their body weight for a short time in the high-dose group, and there was no decrease in other groups (Figure S5). In the muscle (Figure 6A), mild inflammatory cell infiltration, edema, and hemorrhage were observed from 4 to 24 h after immunization. The eLNPs, LNPs-RBD, DOTAP, and DNA groups presented obvious features of pathological injury, such as widening of the interstitial space, after 48 h. In addition, the injection site was red and swollen in the early stage; white scars began to appear at 4 days in the LNPs-RBD, eLNPs, and DOTAP groups, and the remaining groups began to recover (Figure S6). We also observed pathological injuries in the heart (Figure 6B); from 48 h to 7 d after immunization, some cardiomyocytes became thinner, scattered hypertrophic cardiomyocytes appeared, moderate degeneration and necrosis of cardiomyocytes appeared, and the contractile components of the myocardial fibers dissolved and disappeared. Tissue recovery began at 14 days in the DNA-immunized group and at 7 days in the other groups. Notably, the degree of pathological injury in the heart after immunization with dissociative DNA was greater than or equivalent to that after immunization with LNPs-DNA. In the liver (Figure 6C), obvious pathological injuries presented first in the DOTAP immunization group at 4 h, and then pathological injuries presented in the other groups. A few enlarged portal areas with vascular congestion and loose cytoplasm were observed. From 48 h to 7 d after immunization, the liver cells were swollen and degenerated, and moderate inflammatory infiltration was observed in the portal areas and hepatic lobules. In addition, we found that minor inflammatory responses and no obvious pathological injuries were present in various tissues after immunization with PBS (Figures S7 and S8). These findings demonstrated that pathological injuries were induced at 4 h after immunization, and the mice recovered after 7–28 days. Importantly, pathological injuries were less common in the 5 μg dose group than in the 10 μg dose group (Figure 6D). Obvious pathological injuries were observed in the lungs, heart, and liver after immunization with DNA-encapsulated DOTAP-based LNPs, and mice recovered from most injuries later. (A–C) H&E staining was performed to detect pathological injuries in the muscle (A), heart (B), and liver (C) of mice immunized by an intramuscular injection of LNP components, including eLNPs, LNPs-DNA (5 and 10 μg), DOTAP, DNA, DOPE, and DMG-PEG2000. The tissues were collected at 4 h, 24 h, 48 h, 4 days, 8 days, 14 days, and 28 days after immunization. The red arrow points to vascular congestion and tissue hemorrhage; the blue arrow indicates inflammatory cell infiltration, disordered arrangement, and partial rupture of myofibrils; and the black arrow indicates necrosis and tissue disintegration of cells. (D) Pathology scores of the muscle, heart, and liver samples were obtained for each group, and the scoring rules are described in detail in Table S2. Discussion LNPs are highly effective at delivering nucleic acids and triggering a strong innate immune response and, thus, are of great interest for use in vaccine research and development. According to previous reports, DOTAP is one of the most popular cationic lipids used in vaccine formulation and development studies;23,24 however, its wider application has been limited by the obvious inflammation and other side immune reactions. In this work, we described leadingly the delivery efficacy, biodistribution, pathological tissue injury, and inflammatory response in various tissues of a microfluidically prepared DOTAP-based LNP delivery system. We demonstrated that DOTAP-based LNPs exhibited a multilayered structure with a size of approximately 80 nm, and the encapsulation of DNA by LNPs allowed the DNA to be delivered into cells more efficiently, resulting in more DNA being distributed with long durability and persisting in the muscle, lungs, and spleen. Moreover, pathological injuries were induced in the early hours and recovered after 7–28 days. Importantly, pathological injuries were less common in the 5 μg dose group than in the 10 μg dose group. In the same time, anti-RBD antibody levels appeared at 7 days after immunization, and higher levels were detected in the LNP-RBD (10 μg) group than in the dissociative DNA (10 μg) group from 14 days, while no significant difference was observed between the LNPs-RBD (10 μg) group and the LNPs-RBD (5 μg) group at 28 days. On the basis of the above findings, we concluded that DOTAP-based LNPs have obvious advantages in localization to the lungs and spleen, and inflammatory responses and pathological injuries occur in the muscle, heart, and liver in a dose-dependent manner. Several factors influence the NP uptake process, including size, charge, shape, and rigidity, and a smaller size with a positive charge and a rigid structure seem to be the most favorable properties to facilitate cellular uptake.25 We found that microfluidically prepared DOTAP-based LNP exhibited a multilayered spherical structure with a size of approximately 80 nm and a zeta potential charge of approximately 17.0. Previous studies have shown that positively charged nanoparticles tend to accumulate in the lungs;26 interestingly, our results demonstrated that DNA-encapsulated DOTAP-based LNP could transport and deliver DNA into the lungs and spleen with high efficiency and persistence. We speculated that the structure affected the zeta potential, possibly by increasing the number of positive charges from DOTAP exposed and present around LNP-DNA. Perhaps more positive charges from DOTAP were exposed and present around the LNPs-DNA, while more positive charges from DOTAP were blocked inside eLNPs, although the negative charge in DNA could neutralize the positive charge in LNP-DNA. Overall, maybe the size of 80 nm and the positive charge improved the transfection efficiency. According to previous reports, the toxicity, reactogenicity, and toxicodynamics of LNP seem to be affected by multiple factors including particle size, zeta potential, ionizable lipid chemistry, PEG length, and payload reactogenicity,27 and lipoplexes are generally more toxic to a variety of cell types at higher charge ratios, larger sizes, and higher doses.28 In addition, DNA and RNA can be sensed by Toll-like receptors,29 and an excess of type I IFN can induce the production of proinflammatory cytokines.30 In our study, in the muscle, heart, and liver, LNPs exhibited high abundance at early stages but disappeared before 48 h, and in the lungs and spleen, LNPs exhibited obvious and persistent abundance, disappearing after 7 days. Consistently, we found that inflammation was the most severe in the muscle, followed by the heart and liver, and importantly, most innate immune activation occurs due to DOTAP components, and LNPs-RBD, eLNPs, and DOTAP could trigger the release of a variety of cytokines (IL-6, IFN-α, and GM-CSF) and chemokines (CXCL1, CXCL2, CXCL5, and CXCL13) in the muscle, heart, and liver. At the same time, obvious pathological injuries were induced early in the muscle, heart, and liver, and the mice recovered from these injuries after 7–28 days, and LNP-DNA, eLNP, and DOTAP immunizations had obvious side effects. These results suggested that DOTAP and DNA might play important roles in inflammation response and pathological injuries. Ionizable cationic lipids have been developed to mitigate the toxicity of quaternary ammonium lipids, like DOTAP. Whereas DOTAP, as one of the cationic helper lipids, is still being used in delivering mRNA or pDNA to the different tissues, DOTAP could promote the location of LNPs in target tissues, and DOTAP has been used as a helper lipid in the ionizable cationic lipids-based LNPs, and microfluidically prepared DOTAP-based nanoadjuvants (<100 nm) showed a better T-cell response than DOTAP-based LNPs prepared via the lipid film hydration method. Here, we prepared multilayered liposomes encapsulating DNA through the mixture of DOTAP, DOPE, cholesterol, and DMG-PEG2000 using a microfluidics system and then investigated the distribution and abundance of LNPs and DNA, antigen expression, and specific immune responses. We observed that the DOTAP-based LNPs had a broad tissue distribution, and both the LNP and DNA presented durably with obvious abundance in the lungs and spleen after immunization with DNA-encapsulated DOTAP-based LNPs, whereas DNA was less abundant after immunization with dissociative DNA. These findings suggest that DOTAP-based LNPs have obvious advantages for delivery to the lungs and spleen. Importantly, we detected a brief but noticeable inflammatory response and recoverable pathological injuries in the muscle, heart, and liver after LNP injection, and these side effects decreased when the immunization dose decreased. Further research is still needed to reduce the toxicity and improve the stability and biodistribution of LNPs.